Seizure risk with AVM Treatment or Conservative Management
Neurol 79:500-507, Josephson, C.B.,et al, 2012
Position Statement on the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
Neurol 68:1249-1250,1245, Liow,K.,et al, 2007
Practice Parameter: Treatment of the Child with a First Unprovoked Seizure
Neurol 60:166-175, Hirtz,D.,et al, 2003
Is There a Neurologist on the Flight?
Neurol 58:1739-1744,1717, Sirven,J.I.,et al, 2002
A Comparison of Lorazepam,Diazepam,and Placebo for the Treqatment of Out-of-Hospital Status Epilepticus
NEJM 345:631-637,689, Alldredge,B.K.,et al, 2001
When to Start and Stop Anticonvulsant Therapy in Children
Arch Neurol 56:1073-1077, Greenwood,R.S.&Tennison,M.B., 1999
Parenteral Fosphenytoin:Efficacy and Economic Considerations
The Neurologist 4:S30-S34, Ramsay,R.E.&Wilder,B.J., 1998
Incidence and Clinical Consequence of the Purple Glove Syndrome in Patients Receiving Intravenous Phenytoin
Neurol 51:1034-1039,942, O'Brien,T.J.,et al, 1998
New Antiepileptic Drugs:A Systematic Review of Their Efficacy and Tolerability
BMJ 313:1169-1174, 1157, 1158996., Marson,A.G.,et al, 1996
A Pharmacoeconomic Eval of IV Fosphenytoin (Cerebyx) vs IV Phenytoin (Dilantin) in Hosp ER Dept
Clin Therapeutics 18:953-966, Marchetti,A.,et al, 1996
Rational Polypharmacy in the Treatment of Epilepsy
(Ed) , Neurol (suppl) 45:S1-S38., Wilder,B.J., 1995
Drugs for Epilepsy
The Medical Letter, 37:37-401995., , 1995
Magnetic Resonance Imaging
NEJM 328:708-716, 785-7911993., Edelman,R.R.&Warach,S., 1993
Diagnosis and Management of Cerebral Venous Thrombosis:A Scientific Statement From the American Heart Association
Stroke 55:e77-e90, Saposnik,G.,et al, 2024
Mortality and Causes of Death in Children with Cerebral Palsy with Scoliosis Treated with and without Surgery
Neurol 101:e1787-e1792, Ahonen,M.,et al, 2023
Cerebral Venous Thrombosis
NEJM 385:59-64, Ropper, A.H. & Kline, J.P., 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Deprescribing in Epilepsy
JAMA Neurol 77:673-674, Terman, S.W.,et al, 2020
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Subarachnoid Hemorrhage
NEJM 377:257-266, Lawton, M.T. & Vates, G.E., 2017
Evidence-Based Guideline Update: Vagus Nerve Stimulation for the Treatment of Epilepsy
Neurol 81:1453-1459, Morries, G.L.,et al, 2013
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Intracerebral Haemorrhage
Lancet 373:1632-1644, Qureshi,A.I.,et al, 2009
The SANAD Study of Effectiveness of Carbamazepine,Gabapentin,Lamotrigine,Oxcarbazepine,or Topiramate for Treatment of Partial Epilepsy:An Unblinded Randomised Controlled Trial
Lancet 369:1000-1015, Marson,A.G.,et al, 2007
American Academy of Neurology Position Statement on Physician Reporting of Medical Conditions That May Affect Driving Competence
Neurol 68: 1174-1177,1170, Bacon,D.,et al, 2007
Sudden Unexpected Death in Epilepsy (SUDEP): Dont Ask, Dont Tell?
JNNP 77:199-202, Morton,B.,et al, 2006
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
The New Antiepileptic Drugs, Clinical Applications
JAMA 291:615-620, LaRoche,S.M.&Helmers,S.L., 2004
Efficacy and Tolerability for the New Antiepileptic Drugs I: Treatment of New Onset Epilepsy
Neurol 62:1252-1260, French,J.A.,et al, 2004
Efficacy and Tolerability of the New Antiepleptic Drugs II: Treatment of Refractory Epilepsy
Neurol 62:1261-1273, French,J.A.,et al, 2004
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 34:1056-1083, Adams,H.P.,et al, 2003
Epilepsy
NEJM 344:1145-1151, Browne,T.R. & Holmes,G.L., 2001
Spontaneous Intracerebral Hemorrhage
NEJM 344:1450-1460, Qureshi,A.I.,et al, 2001
New Drugs:Which Should Be Included in the Formulary?, Epilepsy:All New Drugs Should Be Included
Arch Neurol 57:272-273,275, Pierre-Louis,S.J.C., 2000
Restrictions on the Availability of Antiepileptic Drugs
Arch Neurol 57:273-274,275, Bergen,D.C., 2000
Managing Women With Epilepsy
BMJ 320:3-4, Wiebe,S., 2000
Indications for Computed Tomography in Patients With Minor Head Injury
NEJM 343:100-105,138, Haydel,M.J. et al, 2000
Prethrombotic Disorders in Children with Arterial Ischemic Stroke and Sinovenous Thrombosis
Arch Neurol 56:967-971, Bonduel,M.,et al, 1999
Do New Antiepileptic Drugs Justify Their Expense
Arch Neurol 55:1140-1142, Chadwick,D., 1998
A Comparison of Rectal Diazepam Gell and Placebo for Acute Repetitive Seizures
NEJM 338:1869-1875, 19161998., Dreifuss,F.E.,et al, 1998
Treating Repetitive Seizures with a Rectal Diazepam Formulation,A Randomized Study
Neurol 51:1274-1282, Cereghino,J.J.,et al, 1998
Practice Parameter,Management Issues for Women with Epilepsy (Summary Statement)
Neurol 51:944-948, Rpt of the Quality Stnds Subcmte AAN, 1998
Long Term Use of Lamotrigine & Vigabatrin in Severe Refractory Epilepsy:Audit of Outcome
BMJ 313:1184-1185, 11571996., Walker,M.C.,et al, 1996
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
The Role of Epilepsy Centers in Delivering Care to Patients with Intractable Epilepsy
Neurol 44:1347-1352, Lesser,R.P., 1994
Epilepsy
JNNP 57:264-277, Chadwick,D., 1994
Electroencephalography
JNNP 57:1308-1319, Binnie,C.D.&Prior,P.F., 1994